Chronic Lymphocytic Leukemia | Clinical

FDA Approves New Tablet Form for Acalabrutinib

August 05, 2022

Acalabrutinib’s new tablet formulation has been granted FDA approval for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and relapsed or refractory mantle cell lymphoma.

Zanubrutinib Displays PFS Benefit Over Bendamustine/Rituximab in CLL and SLL

August 01, 2022

In the first comparison of zanubrutinib vs chemoimmunotherapy, zanbrutinib was shown to improve progression-free survival in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, and may be less toxic.